Ensysce Biosciences raises over $21 million in Series C preferred stock private placement

• Ensysce Biosciences entered a private financing to sell 120,260 shares of Series C Preferred Stock for about $43 million in two tranches.
• Initial tranche closed Aug. 7, raising more than $21 million in gross proceeds.
• Second tranche remains pending, subject to a clinical trial milestone.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ensysce Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-039898), on August 24, 2026, and is solely responsible for the information contained therein.